Erdosteine enhances mucociliary clearance in rats with and without airway inflammation
- PMID: 10334633
- DOI: 10.1016/s1056-8719(98)00053-7
Erdosteine enhances mucociliary clearance in rats with and without airway inflammation
Abstract
Erdosteine is a new homocysteine-derived expectorant and has been reported to have many mucolytic effects. In this report, we studied the activities of erdosteine on mucociliary clearance in normal and airway-inflammation-induced rats. In normal rats, erdosteine at doses of 100-600 mg/kg significantly promoted mucociliary clearance. However, erdosteine did not change the concentrations of mucopolysaccharides in bronchoalveolar lavage fluid (BALF). In the LPS-instillated rats, the mucociliary clearance was inhibited and the number of inflammatory cells, albumin concentration, and mucopolysaccharides concentration in BALF were increased. Erdosteine at doses of 100-600 mg/kg significantly attenuated the inhibition of mucociliary clearance and the increase of inflammatory cells, however, it did not prevent the increase of albumin and mucopolysaccharides. Other mucolytic drugs which are ambroxol and S-carboxymethylcysteine, had no effect. These results indicate that erdosteine promotes the mucociliary clearance in normal and airway-inflammation-induced rats.
Similar articles
-
Mucolytic and antitussive effects of erdosteine.J Pharm Pharmacol. 1999 Aug;51(8):959-66. doi: 10.1211/0022357991773230. J Pharm Pharmacol. 1999. PMID: 10504037
-
The effect of erdosteine on airway defence mechanisms and inflammatory cytokines in the settings of allergic inflammation.Pulm Pharmacol Ther. 2019 Feb;54:60-67. doi: 10.1016/j.pupt.2018.11.006. Epub 2018 Nov 28. Pulm Pharmacol Ther. 2019. PMID: 30502381
-
Effect of erdosteine and its metabolites on tracheobronchial mucus production and transport.Drugs Exp Clin Res. 1988;14(11):693-8. Drugs Exp Clin Res. 1988. PMID: 3246214
-
Erdosteine.Drugs. 1996 Dec;52(6):875-81; discussion 882. doi: 10.2165/00003495-199652060-00009. Drugs. 1996. PMID: 8957158 Review.
-
Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases.Pulm Pharmacol Ther. 2018 Dec;53:80-85. doi: 10.1016/j.pupt.2018.10.005. Epub 2018 Oct 21. Pulm Pharmacol Ther. 2018. PMID: 30352285 Review.
Cited by
-
Erdosteine: antitussive and anti-inflammatory effects.Lung. 2008;186 Suppl 1:S70-3. doi: 10.1007/s00408-007-9065-3. Epub 2008 Jan 10. Lung. 2008. PMID: 18185958 Review.
-
Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.Drugs. 2020 Nov;80(17):1799-1809. doi: 10.1007/s40265-020-01412-x. Drugs. 2020. PMID: 33025535 Free PMC article. Review.
-
The effects of isoniazid on hippocampal NMDA receptors: protective role of erdosteine.Mol Cell Biochem. 2005 Sep;277(1-2):131-5. doi: 10.1007/s11010-005-5778-x. Mol Cell Biochem. 2005. PMID: 16132724
-
Hyper-osmolarity and calcium chelation: Effects on cystic fibrosis mucus.Eur J Pharmacol. 2015 Oct 5;764:109-117. doi: 10.1016/j.ejphar.2015.06.051. Epub 2015 Jun 30. Eur J Pharmacol. 2015. PMID: 26134505 Free PMC article.
-
Effects of the expectorant drug ambroxol hydrochloride on chemically induced lung inflammatory and neoplastic lesions in rodents.J Toxicol Pathol. 2018 Oct;31(4):255-265. doi: 10.1293/tox.2018-0012. Epub 2018 Jun 9. J Toxicol Pathol. 2018. PMID: 30393429 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical